Dalbavancin Sequential Therapy for Gram-Positive Bloodstream Infection: A Multicenter Observational Study
Authors:
Open Access
- 1 March 2024
- journal article
- research article
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 13 (3) , 565-579
Abstract
Introduction Long-acting lipoglycopeptides such as dalbavancin may have utility in patients with Gram-positive bloodstream infections (BSI), particularly in those with barriers to discharge or who require prolonged parenteral antibiotic courses. A retrospective cohort study was performed to provide further multicenter real-world evidence on dalbavancin use as a sequential therapy for Gram-positive BSI. Methods One hundred fifteen patients received dalbavancin with Gram-positive BSI, defined as any positive blood culture or diagnosed with infective endocarditis, from 13 centers geographically spread across the United States between July 2015 and July 2021. Results Patients had a mean (SD) age of 48.5 (17.5) years, the majority were male (54%), with many who injected drugs (40%). The most common infection sources (non-exclusive) were primary BSI (89%), skin and soft tissue infection (SSTI) (25%), infective endocarditis (19%), and bone and joint infection (17%). Staphylococcus aureus accounted for 72% of index cultures, coagulase-negative Staphylococcus accounted for 18%, and Streptococcus species in 16%. Dalbavancin started a median (Q1–Q3) of 10 (6–19) days after index culture collection. The most common regimen administered was dalbavancin 1500 mg as one dose for 50% of cases. The primary outcome of composite clinical failure occurred at 12.2%, with 90-day mortality at 7.0% and 90-day BSI recurrence at 3.5%. Conclusions Dalbavancin may serve as a useful tool in facilitating hospital discharge in patients with Gram-positive BSI. Randomized controlled trials are anticipated to validate dalbavancin as a surrogate to current treatment standards.Keywords
This publication has 30 references indexed in Scilit:
- A Retrospective Analysis of Intravenous vs Oral Antibiotic Step‐Down Therapy for the Treatment of Uncomplicated Streptococcal Bloodstream InfectionsThe Journal of Clinical Pharmacology, 2022
- Outcomes in Patients with Staphylococcus aureus Bacteremia Treated with Dalbavancin in Clinical TrialsInfectious Diseases and Therapy, 2021
- Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infectionsInternational Journal of Antimicrobial Agents, 2020
- Advantages of Outpatient Treatment with Long‐Acting Lipoglycopeptides for Serious Gram‐Positive Infections: A ReviewPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2020
- Transition from intravenous to oral antimicrobial therapy in patients with uncomplicated and complicated bloodstream infectionsClinical Microbiology and Infection, 2020
- Multicenter clinical experience of real life Dalbavancin use in gram-positive infectionsInternational Journal of Infectious Diseases, 2019
- Emergence of a dalbavancin induced glycopeptide/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditisEmerging Microbes & Infections, 2018
- Newer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: systematic review, network meta-analysis and cost analysisClinical Microbiology and Infection, 2018
- Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimenClinical Microbiology and Infection, 2018
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009